MTHFR, Methylation & Homocysteine: The Functional Medicine Guide

Quick answer: Approximately 40% of the general population carries at least one copy of the MTHFR C677T variant, which reduces enzyme activity by 35–70% depending on whether one or two copies are inherited — yet most people with MTHFR variants never experience meaningful clinical consequences when dietary folate is adequate. The clinical significance of MTHFR, COMT, MTR, MTRR, and related methylation cycle variants lies not in the variants themselves, but in how they interact with nutritional status, environmental exposures, and other metabolic demands to determine whether methylation capacity is sufficient for the individual’s biochemical needs.

Methylation is arguably the most fundamental biochemical process in human physiology. Occurring billions of times per second across every cell in the body, methylation reactions transfer a methyl group (–CH₃) to DNA, proteins, neurotransmitters, phospholipids, hormones, and toxins — regulating gene expression, neurotransmitter synthesis and breakdown, hormone metabolism, cardiovascular health, and detoxification capacity. When methylation is impaired, the downstream consequences span cardiovascular disease, psychiatric disorders, cancer risk, reproductive failure, and neurodegenerative disease. When methylation is appropriately supported, it represents one of the highest-yield functional medicine interventions available.

This article provides a comprehensive clinical framework for understanding the methylation cycle, interpreting genetic variants, assessing functional methylation status through biomarkers, and implementing individualized support protocols based on the current peer-reviewed evidence.

The Methylation Cycle: One-Carbon Metabolism Architecture

One-carbon metabolism — the biochemical name for the methylation cycle — is a network of enzymatic reactions that transfer single-carbon (methyl) units between molecules, ultimately converting dietary folate and B12 into the universal methyl donor S-adenosylmethionine (SAM). Understanding this network is essential for interpreting both genetic variants and the biomarker abnormalities that signal methylation dysfunction.

The cycle begins with dietary folate (from food) or folic acid (the synthetic form in supplements and fortified foods). Dietary folate enters cells as polyglutamated forms that must be converted to 5-methyltetrahydrofolate (5-MTHF) — the biologically active folate — through a series of enzymatic steps, with the critical final conversion performed by methylenetetrahydrofolate reductase (MTHFR). 5-MTHF then donates its methyl group to homocysteine, converting it to methionine — a reaction that requires vitamin B12 (as methylcobalamin) as a cofactor and is catalyzed by methionine synthase (MTR, also known as MS).

Methionine is then activated by adenosylation (consuming ATP) to form SAM, the universal methyl donor that participates in over 200 known methylation reactions — methylating DNA (epigenetic gene silencing), RNA, proteins (histone methylation regulating chromatin accessibility), neurotransmitters (converting norepinephrine to epinephrine via PNMT), phosphatidylethanolamine to phosphatidylcholine (essential for cell membrane synthesis and VLDL export from liver), and numerous other substrates. After donating its methyl group, SAM becomes S-adenosylhomocysteine (SAH), then homocysteine. Homocysteine is at the metabolic crossroads: it can re-enter the methylation cycle (remethylation via MTR requiring B12 and 5-MTHF) or be metabolized through the transsulfuration pathway to cystathionine and ultimately cysteine (requiring vitamin B6) and glutathione.

Homocysteine is therefore the central biomarker of methylation cycle function. Elevated homocysteine (hyperhomocysteinemia) signals insufficient remethylation — whether from folate insufficiency, B12 deficiency, MTHFR/MTR enzyme impairment, or excessive methyl group demand. The clinical consequences of hyperhomocysteinemia extend far beyond the cardiovascular risk it signals — homocysteine directly damages endothelial cells, promotes oxidative stress, impairs nitric oxide bioavailability, and drives epigenetic dysregulation through competitive inhibition of SAM-dependent methyltransferases.

MTHFR Variants: What They Actually Mean Clinically

The MTHFR gene encodes methylenetetrahydrofolate reductase, the enzyme that converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-MTHF). Two variants have the most clinical relevance: C677T (rs1801133) and A1298C (rs1801131).

MTHFR C677T: The C677T substitution replaces alanine with valine at position 677, creating a thermolabile enzyme with reduced activity. Heterozygotes (one T allele: approximately 37% of Caucasians) show approximately 35% reduced enzyme activity compared to wild-type. Homozygotes (TT: approximately 10–15% of Caucasians, up to 25% in certain Mediterranean populations) show 60–70% reduced enzyme activity. These individuals produce less 5-MTHF per unit time, meaning they require higher dietary folate intake to maintain equivalent methylation capacity. Critically: at adequate dietary folate intake, the difference in serum homocysteine between C677T homozygotes and wild-type individuals is modest (1–3 µmol/L) — the variant creates a nutritional sensitivity rather than an inevitability of dysfunction.

MTHFR A1298C: The A1298C variant has more modest effects on enzyme activity (~20–30% reduction in homozygotes) and primarily affects the regulatory domain of the enzyme, which modulates MTHFR activity in response to SAM levels. Clinical significance in isolation is mild. However, compound heterozygosity — one C677T plus one A1298C — produces clinically meaningful enzyme impairment equivalent to C677T homozygosity in some studies.

The evidence that MTHFR variants cause harm is entirely mediated through homocysteine. Individuals with C677T TT genotype who maintain normal homocysteine through adequate dietary folate do not show increased cardiovascular risk compared to wild-type controls. The clinical imperative is not to treat the genotype but to assess and normalize homocysteine regardless of genotype — since many individuals without MTHFR variants develop hyperhomocysteinemia through B12 deficiency, renal impairment, hypothyroidism, or medications (methotrexate, metformin, anticonvulsants, proton pump inhibitors).

Homocysteine and Cardiovascular Disease: The Clinical Evidence

The cardiovascular risk associated with elevated homocysteine is among the most consistently replicated findings in nutritional epidemiology. Boushey et al. (1995, JAMA) performed a landmark meta-analysis of 27 studies finding that each 5 µmol/L increase in homocysteine corresponded to a 60% increase in coronary artery disease risk in women and a 30% increase in men — comparable to the risk magnitude of total cholesterol elevation. The Physicians’ Health Study found that homocysteine above 15 µmol/L was associated with a 3.4-fold increased risk of myocardial infarction (Stampfer 1992, JAMA).

The mechanism of homocysteine-mediated cardiovascular damage operates through multiple pathways: direct endothelial cell cytotoxicity and apoptosis, impaired endothelium-dependent vasodilation through nitric oxide scavenging, increased production of reactive oxygen species via oxidative auto-oxidation, activation of coagulation factors (particularly factor V and thrombin), smooth muscle cell proliferation, and epigenetic dysregulation of vascular gene expression through SAH-mediated inhibition of methyltransferases.

Homocysteine’s significance extends beyond cardiovascular disease. Seshadri et al. (2002, NEJM) demonstrated in the Framingham Heart Study cohort that each 5 µmol/L increase in homocysteine doubled the risk of Alzheimer’s disease development — one of the strongest modifiable risk factor associations identified for AD. The VITACOG trial (Smith et al., 2010, PLoS ONE) showed that B6/B12/folate supplementation targeting homocysteine reduction in patients with mild cognitive impairment reduced brain atrophy rate by 30% (p=0.05) and significantly slowed cognitive decline — with effect size proportional to baseline omega-3 status in the subsequent reanalysis (Jernerén 2015, Am J Clin Nutr).

Functional target: optimal homocysteine for clinical practice is 7–10 µmol/L (conventional “normal” reference range extends to 15 µmol/L, which substantially underestimates optimal). Values above 10 µmol/L warrant nutritional intervention; values above 15 µmol/L require investigation of potential secondary causes (B12 deficiency, renal impairment, hypothyroidism) in addition to supplemental support.

COMT: The Catechol-O-Methyltransferase Enzyme

COMT encodes catechol-O-methyltransferase, the enzyme responsible for methylating and thereby inactivating catechol compounds — including dopamine, norepinephrine, epinephrine, and estrogen catechols. The clinically relevant variant is Val158Met (rs4680), commonly described as the “warrior/worrier” polymorphism due to its influence on prefrontal dopamine levels and associated cognitive/behavioral phenotypes.

The Val allele encodes a more active COMT enzyme — more rapidly degrading dopamine and estrogen catechols in the prefrontal cortex and liver. Val/Val homozygotes have 40% higher COMT activity than Met/Met homozygotes, resulting in lower prefrontal dopamine tone. This is associated with: better performance under stress (higher dopamine clearance prevents PFC overactivation), reduced working memory performance under baseline conditions, potentially lower anxiety, and faster estrogen catechol clearance (relevant for hormone-sensitive cancers). The “warrior” label refers to functional advantage in high-stress environments.

Met/Met homozygotes have lower COMT activity — slower dopamine and estrogen catechol degradation. This produces higher prefrontal dopamine tone at baseline, associated with: better working memory and executive function under calm conditions, higher vulnerability to dopamine overactivation under stress (the “worrier” phenotype associated with anxiety, rumination, and performance anxiety), and slower estrogen catechol clearance (associated with estrogen dominance phenotypes and potentially elevated breast cancer risk through accumulation of genotoxic 4-hydroxyestrogen catechols).

COMT activity requires SAM as the methyl donor — making COMT function directly dependent on methylation cycle adequacy. When SAM is depleted (B12 or folate deficiency, stress-driven methyl depletion), COMT activity falls regardless of genotype, impairs catechol clearance, and can produce clinical manifestations of catecholamine excess or estrogen catechol accumulation. This is why COMT-related symptoms (anxiety, hormonal symptoms, caffeine sensitivity) often improve with methylation support even in Val/Val individuals — normalizing SAM availability improves COMT function throughout its physiological range.

Methylation and Epigenetics: The Clinical Significance of DNA Methylation

DNA methylation — the addition of a methyl group to cytosine residues in CpG dinucleotides by DNA methyltransferases (DNMTs) — is the primary epigenetic mechanism through which gene expression is regulated without altering the underlying DNA sequence. Methylated CpG sites generally silence gene expression by recruiting methyl-CpG-binding proteins that compact chromatin. Unmethylated (hypomethylated) promoter CpGs allow transcription factor access and gene activation.

Global DNA hypomethylation — reducing gene silencing capacity — is one of the earliest molecular events in cancer development, observed in virtually all human cancers decades before clinical diagnosis. LINE-1 repeat element methylation (a proxy for global methylation) correlates inversely with cancer risk in prospective studies: Luebeck et al. (2019) demonstrated that each 10% reduction in LINE-1 methylation was associated with a 17% increase in colorectal cancer risk independent of known risk factors.

Promoter-specific hypermethylation silences tumor suppressor genes in cancer — a process directly dependent on SAM availability and DNMT activity. Folate deficiency reduces SAM levels, impairs DNMT function, and promotes both global hypomethylation and aberrant promoter hypermethylation of tumor suppressors including BRCA1, MLH1, and APC. The Cancer Prevention Study II found that women with higher folate intake had 40% lower breast cancer risk (Sellers 2001), with the largest effect in those with low to moderate alcohol intake (alcohol depletes folate and impairs its metabolism).

Histone methylation — another SAM-dependent process — regulates chromatin accessibility and is now recognized as dysregulated in virtually all major diseases. H3K4 trimethylation activates gene expression; H3K27 trimethylation silences it. The balance of histone methyltransferase and demethylase activity determines whether anti-inflammatory, pro-immune, or pro-aging gene expression programs are active. Butyrate (from gut microbial fermentation) inhibits histone deacetylases and shifts chromatin toward anti-inflammatory epigenetic programming — mechanistically linking microbiome health to methylation-dependent epigenetic regulation.

Methylation and Neurotransmitter Synthesis

The nervous system is among the most methyl-demanding tissues in the body. Multiple critical neurotransmitter synthesis steps require methylation or methylation-dependent cofactors:

Serotonin pathway: Serotonin synthesis requires tryptophan hydroxylase (TPH2), aromatic amino acid decarboxylase (B6-dependent), and ultimately methylation for metabolic breakdown via MAO and COMT. SAM donates methyl groups in serotonin catabolism. More critically, adequate folate and B12 maintain the tetrahydrobiopterin (BH4) pool — a cofactor for TPH2 — through their role in the recycling of dihydrobiopterin. BH4 deficiency impairs serotonin, dopamine, and nitric oxide synthesis simultaneously.

Dopamine pathway: Tyrosine hydroxylase (the rate-limiting dopamine synthesis enzyme) requires BH4, making dopamine production folate/B12-dependent through BH4 recycling. DOPA decarboxylase requires pyridoxal-5-phosphate (P5P, active B6). Dopamine is inactivated primarily by COMT (SAM-dependent) and MAO. Norepinephrine synthesis from dopamine requires dopamine β-hydroxylase (vitamin C-dependent). Epinephrine synthesis from norepinephrine requires PNMT (SAM-dependent methylation). The entire catecholamine cascade is therefore critically dependent on methylation cycle adequacy.

Histamine: Histamine is inactivated by HNMT (histamine N-methyltransferase, SAM-dependent) and DAO. In individuals with impaired methylation, histamine degradation via the HNMT pathway slows — potentially contributing to histamine intolerance phenotypes that overlap with MCAS. This explains the clinical observation that methylation support sometimes reduces histamine sensitivity even in individuals without true MCAS.

Myelin synthesis: Phosphatidylcholine — the predominant phospholipid in myelin sheaths — is synthesized in part through the PEMT (phosphatidylethanolamine N-methyltransferase) pathway, which requires three sequential SAM-dependent methylation steps. B12 deficiency causing methylation insufficiency therefore directly impairs myelin synthesis and maintenance — explaining the neurological consequences of B12 deficiency (subacute combined degeneration of the spinal cord) that can precede megaloblastic anemia.

Methylation and Estrogen Metabolism: The Estrobolome and COMT

Estrogen metabolism requires methylation at multiple steps. Phase II hepatic detoxification of estrogen catechols (2-hydroxyestrone and 4-hydroxyestrone, produced from estradiol by CYP1A2 and CYP1B1) requires COMT for methylation to methoxyestrogens — clearing these reactive intermediates before they can form depurinating DNA adducts. The genotoxic 4-hydroxyestrone — methylated by COMT to the protective 4-methoxyestrone — is implicated in estrogen-driven breast cancer pathogenesis when clearance is inadequate.

Clinically, COMT Met/Met homozygotes combined with low SAM availability (from B12 or folate insufficiency, high stress, or MTHFR TT genotype) represent individuals with greatest impairment in estrogen catechol clearance. The DUTCH (Dried Urine Test for Comprehensive Hormones) panel specifically measures 2-OH and 4-OH estrogen metabolites, their methylated derivatives, and the 2-OH:2-MeO ratio — providing a direct assessment of COMT activity in estrogen metabolism. Impaired estrogen methylation manifests as elevated 4-OH metabolites and reduced methyloestrogen ratios on DUTCH testing, and is clinically associated with estrogen dominance symptoms (heavy periods, fibrocystic breasts, PMS, bloating) beyond what circulating estradiol levels alone would predict.

The estrobolome — the subset of gut microbiome species that produce β-glucuronidase, deconjugating excreted estrogen metabolites and returning them to enterohepatic circulation — interacts with methylation: reduced methylation of estrogen catechols generates more genotoxic metabolites that even adequate estrobolome function cannot compensate for. Combined support through methylation optimization (5-MTHF, methylcobalamin, B6 for transsulfuration support) and estrobolome support (calcium D-glucarate to inhibit β-glucuronidase, DIM 200–400mg to shift 2-OH:16-OH ratios, and microbiome diversity maintenance) addresses both sides of estrogen detoxification.

Functional Methylation Assessment: The Biomarker Panel

Genetic variants alone do not determine methylation status — functional biomarkers provide the ground truth. A comprehensive functional methylation assessment includes:

Homocysteine (plasma): The primary methylation cycle biomarker. Target 7–10 µmol/L. Elevations guide aggressive folate/B12 support; very low homocysteine (<5 µmol/L) can also occur with over-methylation and requires assessment. Collect fasting — post-meal homocysteine is modestly lower.

Serum B12: Standard serum B12 is poorly sensitive for functional deficiency — levels down to 200 pg/mL are conventionally “normal” despite functional deficiency producing neurological symptoms. Optimal functional target: 700–900 pg/mL. Supplement false elevation (oral B12 supplements raise serum B12 even with malabsorption) necessitates functional B12 markers.

Methylmalonic acid (MMA): MMA accumulates when adenosylcobalamin (the mitochondrial form of B12) is insufficient for methylmalonyl-CoA mutase — a B12-dependent enzyme in mitochondrial energy metabolism. Elevated plasma or urine MMA is a specific and sensitive marker of functional B12 deficiency, remaining elevated even when serum B12 appears normal. Target: plasma MMA <0.27 µmol/L, urine MMA <3.8 µg/mg creatinine.

Red blood cell folate: RBC folate reflects long-term folate status (erythrocyte lifespan 120 days) and is more clinically relevant than serum folate (reflects recent intake). Optimal target: 400–600 ng/mL. Values below 280 ng/mL indicate deficiency independent of dietary folate intake.

Plasma 5-MTHF (if available): Specialty labs can measure plasma 5-methyltetrahydrofolate directly, distinguishing between folic acid (the synthetic oxidized form that does not convert to 5-MTHF as efficiently in C677T TT individuals) and 5-MTHF bioavailability. Useful for patients supplementing folic acid who are not achieving adequate 5-MTHF levels.

SAM/SAH ratio: The ratio of S-adenosylmethionine to S-adenosylhomocysteine provides a direct measure of methylation capacity — the “methylation potential.” Available through specialized labs (Doctors Data, Genova); SAM/SAH ratio below 4.5 indicates methylation insufficiency even with normal homocysteine in some clinical presentations.

Organic acids panel: Includes methylmalonic acid, succinate, and other TCA cycle intermediates that reflect mitochondrial B12 and folate adequacy; formiminoglutamic acid (FIGLU) reflects folate insufficiency; xanthurenic acid reflects B6 insufficiency for transsulfuration pathway function.

DUTCH panel: For estrogen metabolite methylation assessment — 2-OH, 4-OH, and 16-OH estrogen metabolites, 2-MeO:2-OH ratio (direct proxy for COMT activity), cortisol metabolites (cortisol methylation via COMT also measured), and melatonin metabolites.

Methylation Support Protocol: Individualized by Genotype and Biomarker Status

The appropriate methylation support protocol depends on the interaction of genotype (which creates susceptibility) with biomarker status (which confirms whether impairment is present) and clinical symptoms (which guide urgency and intervention intensity).

For MTHFR C677T heterozygotes or homozygotes with normal homocysteine (≤10 µmol/L): Dietary folate optimization (dark leafy greens, legumes, liver) is the primary intervention. Supplementation with 400–800 mcg 5-MTHF (rather than folic acid) provides bioavailable folate without relying on MTHFR conversion. Methylcobalamin 1000 mcg daily (sublingual for superior absorption vs oral in individuals with reduced intrinsic factor or gastric acidity). Monitor homocysteine annually.

For elevated homocysteine (10–15 µmol/L) regardless of genotype: 5-MTHF 800 mcg–1000 mcg daily, methylcobalamin 1000–5000 mcg daily (sublingual preferred), pyridoxal-5-phosphate (P5P) 50–100 mg daily (B6 active form for transsulfuration pathway and CBS enzyme support), riboflavin (B2) 400 mg daily (MTHFR requires riboflavin as a cofactor — riboflavin supplementation has been shown to reduce homocysteine specifically in C677T TT carriers by an additional 22% beyond folate alone, McNulty 2006). Target homocysteine normalization to <10 µmol/L with 8–12 week recheck.

For severe hyperhomocysteinemia (>15 µmol/L): Rule out secondary causes first — B12 deficiency (MMA), renal impairment (creatinine, eGFR), hypothyroidism (TSH, free T3), and medication effects (metformin, methotrexate, anticonvulsants, PPIs, nitrous oxide). Then implement aggressive supplementation: 5-MTHF 1–5 mg daily, hydroxocobalamin or adenosylcobalamin 1000–5000 mcg injections or sublingual (oral absorption unreliable at these levels), P5P 100 mg, riboflavin 400 mg. Trimethylglycine (TMG/betaine) 1–3 g daily provides an alternative BHMT-dependent remethylation pathway that bypasses MTHFR and MTR, reducing homocysteine independently of folate/B12 status — valuable in refractory cases.

For COMT Met/Met with estrogen dominance or anxiety symptoms: Prioritize SAM availability through methylation foundation (5-MTHF + methylcobalamin). Add DIM 200–400 mg daily (shifts estrogen metabolism toward 2-OH pathway, reducing substrate load on COMT). Magnesium glycinate 400 mg (COMT requires magnesium as a cofactor). Consider SAMe supplementation (400–1600 mg daily, titrated) in individuals with confirmed depression, liver dysfunction, or documented methylation insufficiency — SAMe directly provides the methyl donor, bypassing MTHFR and MTR. Cruciferous vegetables provide sulforaphane and indole-3-carbinol that upregulate CYP1A2 relative to CYP1B1, shifting estrogen catechol production toward the less genotoxic 2-OH pathway.

Important caution — over-methylation: A subset of individuals experience adverse effects from high-dose methyl donors — increased anxiety, irritability, insomnia, and palpitations — particularly Met/Met COMT carriers who already have reduced catecholamine methylation. Introducing 5-MTHF and methylcobalamin slowly (starting low, titrating over weeks), and not adding SAMe without confirming methylation deficiency, reduces this risk. Hydroxocobalamin (rather than methylcobalamin) is often better tolerated in anxious individuals, as it provides B12 substrate without directly loading the methyl pool.

Methylation and Psychiatric Disorders: The MTHFR-Depression Connection

The relationship between methylation cycle impairment and depression has moved from hypothesis to clinical utility. A meta-analysis by Gilbody et al. (2007, American Journal of Psychiatry) pooled 15 studies and found that C677T TT homozygotes had 36% higher risk of depression compared to CC wild-type (OR 1.36, 95% CI 1.09–1.70). The mechanism: impaired 5-MTHF production reduces SAM availability for methylation of monoamine neurotransmitters, limits BH4 synthesis (reducing serotonin and dopamine production rates), and may directly impair monoamine neurotransmitter receptor methylation patterns in neural tissue.

5-MTHF has been studied as both monotherapy and adjunctive treatment for depression. Papakostas et al. (2012, American Journal of Psychiatry) published an RCT of 75 depressed patients who had not responded to SSRI therapy. L-methylfolate 15 mg added to SSRI treatment produced significantly greater response and remission rates compared to placebo added to SSRI — with response rate 32.3% vs 14.6% (p=0.04). Specifically, the benefit was concentrated in patients with low folate, high inflammatory biomarkers, and MTHFR TT genotype — demonstrating that l-methylfolate supplementation is a precision psychiatric intervention, not a universal antidepressant.

SAMe has the strongest evidence base of any natural compound for depression: a 2002 meta-analysis of 28 RCTs by Papakostas et al. found SAMe significantly superior to placebo and equivalent to tricyclic antidepressants in efficacy (with substantially better tolerability), with effect sizes comparable to SSRIs. SAMe 800–1600 mg daily has demonstrated particular benefit in: treatment-resistant depression with documented methylation insufficiency, depression comorbid with liver disease (SAMe has independent hepatoprotective effects), and patients wishing to avoid pharmaceutical antidepressants who have documented MTHFR TT + elevated homocysteine.

Neural Tube Defects, Pregnancy, and Periconceptional Methylation

The most thoroughly established clinical consequence of MTHFR and methylation insufficiency is neural tube defect (NTD) risk in pregnancy. The landmark MRC Vitamin Study (1991, Lancet) demonstrated that folic acid 4 mg/day periconceptionally reduced NTD recurrence risk by 72%. Subsequent analysis demonstrated that C677T TT mothers have approximately 2-fold higher NTD risk in offspring — risk substantially normalized by adequate periconceptional folate.

For women with C677T TT genotype planning pregnancy, 5-MTHF 400–800 mcg (rather than folic acid alone) is the preferred periconceptional folate supplementation — avoiding the need to rely on MTHFR for conversion of folic acid to 5-MTHF. Women with recurrent pregnancy loss (RPL) should be evaluated for methylation cycle dysfunction, including MTHFR genotype, homocysteine, RBC folate, B12/MMA, antiphospholipid antibodies (associated with MTHFR and hyperhomocysteinemia), and thyroid function. Elevated homocysteine directly impairs trophoblast invasion and placental development — normalizing homocysteine below 10 µmol/L before conception reduces RPL risk.

The clinical recommendation has evolved: rather than testing MTHFR genotype in all pregnant women (since the intervention is the same regardless of genotype — adequate folate), periconceptional supplementation with 5-MTHF-containing prenatal vitamins rather than synthetic folic acid provides optimal coverage regardless of MTHFR status. For women with documented recurrent pregnancy loss or neural tube defect history, 5-MTHF 5 mg daily (prescription dose in the UK/Canada, available OTC in the US) is standard practice.

Frequently Asked Questions About MTHFR and Methylation

Should everyone get MTHFR testing?

MTHFR genotyping provides useful context but should not replace functional biomarker assessment. A normal homocysteine (7–10 µmol/L) in someone with MTHFR TT indicates adequate compensatory folate intake and no urgent intervention need. Conversely, elevated homocysteine in someone with MTHFR CC (wild-type) requires assessment and treatment regardless of genotype. The functional panel — homocysteine, MMA, RBC folate, B12 — provides more actionable information than genotype alone. That said, MTHFR genotyping adds value in: family history of cardiovascular disease or neural tube defects, recurrent pregnancy loss, treatment-resistant depression, or identifying the appropriate B12 form (hydroxocobalamin vs methylcobalamin) and folate form (5-MTHF vs folic acid) for supplementation.

Is methylcobalamin always better than cyanocobalamin?

Methylcobalamin and adenosylcobalamin are the active B12 coenzyme forms, while cyanocobalamin and hydroxocobalamin are precursor forms requiring conversion. For most individuals, cyanocobalamin is effectively converted and is the most stable and cost-effective form. For individuals with impaired detoxification capacity (hereditary conditions affecting cyanide metabolism, heavy smokers, or high-dose supplementation), hydroxocobalamin is preferred. For MTHFR TT individuals or those with methylation insufficiency, methylcobalamin provides the methyl donor directly. Some anxious individuals with COMT Met/Met genotype do better with hydroxocobalamin than methylcobalamin — the additional methyl load from methylcobalamin can transiently worsen anxiety through dopamine overflow.

Can folic acid supplementation be harmful in MTHFR TT?

High-dose synthetic folic acid (above 400 mcg) can accumulate as unmetabolized folic acid (UMFA) in MTHFR TT individuals, whose reduced MTHFR activity limits conversion to 5-MTHF. UMFA has been proposed to compete with 5-MTHF for cellular uptake and folate receptor binding, potentially reducing 5-MTHF transport into cells despite high total circulating folate. This is why MTHFR TT individuals should use 5-MTHF rather than folic acid supplementation, and why food-based folate (dark leafy greens, legumes, liver — which provides reduced folate polyglutamates rather than synthetic folic acid) is nutritionally preferable for this population.

Methylation optimization represents one of the highest-yield personalized medicine interventions available — with downstream effects on cardiovascular risk, neurotransmitter function, cancer epigenetics, reproductive outcomes, hormonal metabolism, and psychiatric health. If you are experiencing unexplained cardiovascular risk factors, treatment-resistant depression, reproductive challenges, estrogen dominance symptoms, or simply want comprehensive methylation assessment, The Private Practice offers individualized functional medicine evaluation including complete methylation biomarker panels and genotype-informed protocols. Contact us at (810) 206-1402 to schedule a consultation.

MTHFR, Methylation & Homocysteine: The Lab Test Most Doctors Never Order